Tauriga Sciences Inc. Showcases the Blister Pack Design for its 8th  Tauri-Gum SKU, Golden Raspberry Flavor / Vitamin D3 Infused

Each Piece of Chewing Gum is Infused with 50 Micrograms (“ug”) or 2,000 International Units (“IU”) of Vitamin D3 (“Cholecalciferol”)

NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) --  via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today showcased the Blister Pack design for its 8th Tauri-Gum™ SKU: Golden Raspberry Flavor / Infused with Vitamin D3 (“D3 or Cholecalciferol”).  Each piece of chewing gum is in infused with 50 Micrograms (“ug”) or 2,000 International Units (“IU”) of Vitamin D3.  The Company now has 3 distinct, Cannabinoid-Free SKUs of Tauri-Gum™ to complement its 5 SKUs of CBD & CBG infused products.  These 3 complementary Cannabinoid-Free Tauri-Gum™ SKUs create significant potential opportunities for the Company.

In other news, the Company can confirm that it has increased the CBD and CBG infusion concentrations to 25 Milligrams (“mg”) per piece of chewing gum.  This takes effect immediately and is incorporated into the Company’s current large production run (as referenced in its press release, dated: February 10, 2021).  For this large production run (currently being completed), the Company has allocated $267,750.

Lastly, the Company continues to experience overall strength and growth in its highest margin E-Commerce business segment.  As of this morning, March 1, 2021, the Company received its 5,515th  E-Commerce order.

The Tauri-Gum™ Product Line now consists of 8 distinct SKUs:

[3] Cannabidiol (“CBD”) Infused SKUs:

(i)  Color: Red - Pomegranate Flavor (10-25mg)

(ii)  Color: Orange - Blood Orange Flavor (10-25mg)

(iii) Color: Blue - Mint Flavor (10-25mg)

[2] Cannabigerol (“CBG”) Infused SKUs:

(iv)  Color: Yellow - Peach-Lemon Flavor (10-25mg)

(v)  Color: Purple - Black Currant Flavor (15-25mg)

[3] Cannabinoid-Free (Vitamin C + Zinc, Caffeine, Vitamin D3) Infused SKUs:

(vi)  Color: Green - Pear Bellini Flavor (60mg Vitamin C + 10mg Zinc)

(vii)  Color: Pink - Cherry Lime Rickey Flavor (50mg Caffeine)

(viii) Color: Coral/Gold - Golden Raspberry Flavor (50ug or 2,000 IU)


Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.


Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website:   www.tauriga.com

E-Commerce Website:  www.taurigum.com


03_01_2021 PR Image